

## LONZA GROUP AG

ISIN: CH0013841017 WKN: 1384101

## Overview

2024/09/10 12:51:00

Price  
557.50 CHFDifference ▲ 3.89% (20.90)

## General attributes

|                |                                    |
|----------------|------------------------------------|
| ISIN           | CH0013841017                       |
| Symbol         | LONN                               |
| Exchange       | London Stock Exchange              |
| Currency       | CHF                                |
| Sector         | Chemical / Pharmaceutical / Health |
| Security type  | Stock                              |
| Market cap (m) | 39,485 EUR                         |
| Benchmark      | SWISS MARKET INDEX                 |

## Market data

|                   |                 |
|-------------------|-----------------|
| Bid (Bid size)    | 429.20 CHF (11) |
| Ask (Ask size)    | 508.40 CHF (3)  |
| Open              | 557.50 CHF      |
| High              | 557.50 CHF      |
| Low               | 557.50 CHF      |
| Close (prev. day) | 536.60 CHF      |
| VWAP              | 557.50 CHF      |
| Volume (pcs)      | 4,200           |
| Trading volume    | 2,341,500.00    |
| Number of trades  | 1               |
| Last size         | 4,200           |

## Futures and Options

|                 |    |
|-----------------|----|
| Related Futures | 30 |
| Related Options | -  |

## PDF Downloads

Company report: LONZA GROUP AG 

5Y



Information about previous performance does not guarantee future performance.  
Source: FactSet

## Recent research

| on sector  | on market   |                       |   |
|------------|---|-----------------------|---|
| Date       |   | Headline              | Download  |
| 2024/09/11 |  | Global Equity Ratings |  |
| 2024/09/05 |  | Global Equity Ratings |  |
| 2024/08/12 |  | Global Equity Ratings |  |
| 2024/07/24 |  | Global Equity Ratings |  |
| 2024/07/12 |  | Global Equity Ratings |  |

## Details

2024/09/10 12:51:00

**Price**  
557.50 CHF

**Difference** ▲ 3.89% (20.90)

## General attributes

|                |                                    |
|----------------|------------------------------------|
| ISIN           | CH0013841017                       |
| Symbol         | LONN                               |
| Exchange       | London Stock Exchange              |
| Currency       | CHF                                |
| Sector         | Chemical / Pharmaceutical / Health |
| Security type  | Stock                              |
| Market cap (m) | 39,485 EUR                         |
| Benchmark      | SWISS MARKET INDEX                 |

## Market data

|                   |                 |
|-------------------|-----------------|
| Bid (Bid size)    | 429.20 CHF (11) |
| Ask (Ask size)    | 508.40 CHF (3)  |
| Open              | 557.50 CHF      |
| High              | 557.50 CHF      |
| Low               | 557.50 CHF      |
| Close (prev. day) | 536.60 CHF      |
| VWAP              | 557.50 CHF      |
| Volume (pcs)      | 4,200           |
| Trading volume    | 2,341,500.00    |
| Number of trades  | 1               |
| Last size         | 4,200           |

## Performance and Risk

|             | 6m     | 1Y     | 3Y     |
|-------------|--------|--------|--------|
| Perf (%)    | -      | -      | -      |
| Perf (abs.) | -      | -      | -      |
| Beta        | -      | -      | -      |
| Volatility  | 516.87 | 347.46 | 199.43 |

5Y



Information about previous performance does not guarantee future performance.  
Source: FactSet

## Price data

|   |                         |
|---|-------------------------|
| Ø price 5 days   Ø volume 5 days (pcs.)     | 557.50 CHF (910)        |
| Ø price 30 days   Ø volume 30 days (pcs.)   | 553.99 CHF (574)        |
| Ø price 100 days   Ø volume 100 days (pcs.) | 507.42 CHF (1,359)      |
| Ø price 250 days   Ø volume 250 days (pcs.) | 426.99 CHF (3,366)      |
| YTD High   date                             | 587.40 CHF (2024/07/31) |
| YTD Low   date                              | 52.25 CHF (2024/06/25)  |
| 52 Weeks High   date                        | 587.40 CHF (2024/07/31) |
| 52 Weeks Low   date                         | 52.25 CHF (2024/06/25)  |

## Arbitrage views

| Exchange <span>⊕</span> | Date       | Time  | Price       | Trading volume (mio.) | Number of trades |
|-------------------------|------------|-------|-------------|-----------------------|------------------|
| Singapore Exchange      | 2011/10/21 | 09:51 | 74.0753 SGD | 0.00                  | 1                |
| SIX Swiss Exchange      | 2024/09/18 | 17:19 | 532.60 CHF  | 59.83                 | 4,686            |
| London Stock Exchange   | 2024/09/10 | 12:51 | 557.50 CHF  | 2.34                  | 1                |
| Hamburg                 | 2019/06/28 | 08:01 | 291.30 EUR  | 0.00                  | 2                |
| Frankfurt               | 2019/06/28 | 15:56 | 293.90 EUR  | 0.02                  | 4                |

|                           |                |       |            |      |  |    |
|---------------------------|----------------|-------|------------|------|--|----|
|                           | 28             |       |            |      |  |    |
| FINRA other OTC<br>Issues | 2024/09/<br>17 | 21:17 | 632.57 USD | 0.00 |  | 3  |
| Duesseldorf               | 2019/06/<br>28 | 08:11 | 291.20 EUR | 0.00 |  | 2  |
| Berlin                    | 2019/06/<br>28 | 18:45 | 296.90 EUR | 0.00 |  | 14 |

# Company profile

## Company Logo



### Contact Details

LONZA GROUP AG

--

Muenchensteinerstrasse 38 - 4002 Basel

Telefon: +41-61-316-81-11

Fax: +41-61-316-91-11

E-mail: media@lonza.com

### PDF Downloads

Company report: LONZA GROUP AG



## Company Profile

Lonza Group AG is engaged in the supply of pharmaceutical, healthcare, and life science products. It operates through the following segments: Biologics, Small Molecules, Cell and Gene, Capsule and Health Ingredients, and Corporate. The Biologics segment serves as contract development and manufacturing partner for biopharmaceuticals, catering customers for all clinical and commercial manufacturing needs throughout the product lifecycle. The Small Molecules segment offers small molecule drug substances and intermediates related services. The Cell and Gene segment includes the Cell and Gene Technologies and Bioscience businesses. The Capsule and Health Ingredients segment provides innovative capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical companies. The Corporate segment refers to finance and accounting, legal, communication, information technology, and human resources functions. The company was founded on October 27, 1897 and is headquartered in Basel, Switzerland.

### Members of Management Board

|                        |                               |
|------------------------|-------------------------------|
| Wolfgang Wienand       | Chairman of Managing Board    |
| Christian Seufert      | Member of Executive Committee |
| Daniel Palmacci        | Member of Executive Committee |
| Gordon Bates           | Member of Executive Committee |
| Jean-Christophe Hyvert | Member of Executive Committee |
| Maria Soler Nunez      | Member of Executive Committee |
| Philippe Deecke        | Member of Executive Committee |

### Board of directors

|                          |                                      |
|--------------------------|--------------------------------------|
| Angelica Kohlmann        | Member of the administrative board   |
| Marion Helmes            | Member of the administrative board   |
| Olivier Verscheure       | Member of the administrative board   |
| Roger Nitsch             | Member of the administrative board   |
| Barbara Richmond         | Member of the administrative board   |
| Christoph Mäder          | Member of the administrative board   |
| Jürgen B. Steinemann     | Member of the administrative board   |
| R. Jean-Marc Sidney Huët | Chairman of the administrative board |